MRI Gadolinium-Based Contrast Media

Gadolinium-based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). They are essential for choosing the most appropriate medical or surgical strategy for patients with serious pathologies, particularly in oncologic, inflammatory, and cardiovascular diseases. However, GBC...

Descripción completa

Detalles Bibliográficos
Autores: Bendszus, Martin, Laghi, Andrea|||0000-0002-3091-7819, Munuera, Josep|||0000-0001-5154-1796, Tanenbaum, Lawrence N., Taouli, Bachir|||0000-0001-6409-1333, Thoeny, Harriet C.
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:304081
Acceso en línea:https://ddd.uab.cat/record/304081
https://dx.doi.org/urn:doi:10.1002/jmri.29181
Access Level:acceso abierto
Palabra clave:Gadolinium-based contrast agents
Gadopiclenol
Magnetic resonance imaging
id ES_fae4e19f9f9b6c38c34cb6fa70e2d829
oai_identifier_str oai:ddd.uab.cat:304081
network_acronym_str ES
network_name_str España
repository_id_str
spelling MRI Gadolinium-Based Contrast MediaMeeting Radiological, Clinical, and Environmental NeedsBendszus, MartinLaghi, Andrea|||0000-0002-3091-7819Munuera, Josep|||0000-0001-5154-1796Tanenbaum, Lawrence N.Taouli, Bachir|||0000-0001-6409-1333Thoeny, Harriet C.Gadolinium-based contrast agentsGadopiclenolMagnetic resonance imagingGadolinium-based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). They are essential for choosing the most appropriate medical or surgical strategy for patients with serious pathologies, particularly in oncologic, inflammatory, and cardiovascular diseases. However, GBCAs have been associated with an increased risk of nephrogenic systemic fibrosis in patients with renal failure, as well as the possibility of deposition in the brain, bones, and other organs, even in patients with normal renal function. Research is underway to reduce the quantity of gadolinium injected, without compromising image quality and diagnosis. The next generation of GBCAs will enable a reduction in the gadolinium dose administered. Gadopiclenol is the first of this new generation of GBCAs, with high relaxivity, thus having the potential to reduce the gadolinium dose while maintaining good in vivo stability due to its macrocyclic structure. High-stability and high-relaxivity GBCAs will be one of the solutions for reducing the dose of gadolinium to be administered in clinical practice, while the development of new technologies, including optimization of MRI acquisitions, new contrast mechanisms, and artificial intelligence may help reduce the need for GBCAs. Future solutions may involve a combination of next-generation GBCAs and image-processing techniques to optimize diagnosis and treatment planning while minimizing exposure to gadolinium. Level of Evidence: 5. Technical Efficacy: Stage 3. 22024-01-0120242024-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/304081https://dx.doi.org/urn:doi:10.1002/jmri.29181reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3040812026-06-06T12:50:31Z
dc.title.none.fl_str_mv MRI Gadolinium-Based Contrast Media
Meeting Radiological, Clinical, and Environmental Needs
title MRI Gadolinium-Based Contrast Media
spellingShingle MRI Gadolinium-Based Contrast Media
Bendszus, Martin
Gadolinium-based contrast agents
Gadopiclenol
Magnetic resonance imaging
title_short MRI Gadolinium-Based Contrast Media
title_full MRI Gadolinium-Based Contrast Media
title_fullStr MRI Gadolinium-Based Contrast Media
title_full_unstemmed MRI Gadolinium-Based Contrast Media
title_sort MRI Gadolinium-Based Contrast Media
dc.creator.none.fl_str_mv Bendszus, Martin
Laghi, Andrea|||0000-0002-3091-7819
Munuera, Josep|||0000-0001-5154-1796
Tanenbaum, Lawrence N.
Taouli, Bachir|||0000-0001-6409-1333
Thoeny, Harriet C.
author Bendszus, Martin
author_facet Bendszus, Martin
Laghi, Andrea|||0000-0002-3091-7819
Munuera, Josep|||0000-0001-5154-1796
Tanenbaum, Lawrence N.
Taouli, Bachir|||0000-0001-6409-1333
Thoeny, Harriet C.
author_role author
author2 Laghi, Andrea|||0000-0002-3091-7819
Munuera, Josep|||0000-0001-5154-1796
Tanenbaum, Lawrence N.
Taouli, Bachir|||0000-0001-6409-1333
Thoeny, Harriet C.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Gadolinium-based contrast agents
Gadopiclenol
Magnetic resonance imaging
topic Gadolinium-based contrast agents
Gadopiclenol
Magnetic resonance imaging
description Gadolinium-based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). They are essential for choosing the most appropriate medical or surgical strategy for patients with serious pathologies, particularly in oncologic, inflammatory, and cardiovascular diseases. However, GBCAs have been associated with an increased risk of nephrogenic systemic fibrosis in patients with renal failure, as well as the possibility of deposition in the brain, bones, and other organs, even in patients with normal renal function. Research is underway to reduce the quantity of gadolinium injected, without compromising image quality and diagnosis. The next generation of GBCAs will enable a reduction in the gadolinium dose administered. Gadopiclenol is the first of this new generation of GBCAs, with high relaxivity, thus having the potential to reduce the gadolinium dose while maintaining good in vivo stability due to its macrocyclic structure. High-stability and high-relaxivity GBCAs will be one of the solutions for reducing the dose of gadolinium to be administered in clinical practice, while the development of new technologies, including optimization of MRI acquisitions, new contrast mechanisms, and artificial intelligence may help reduce the need for GBCAs. Future solutions may involve a combination of next-generation GBCAs and image-processing techniques to optimize diagnosis and treatment planning while minimizing exposure to gadolinium. Level of Evidence: 5. Technical Efficacy: Stage 3.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/304081
https://dx.doi.org/urn:doi:10.1002/jmri.29181
url https://ddd.uab.cat/record/304081
https://dx.doi.org/urn:doi:10.1002/jmri.29181
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425279565299712
score 15.812455

Similares en LA Referencia